培美曲塞联合常规化疗在Ⅲ～Ⅳ期非小细胞肺癌患者中的应用价值

The Application Value of Pemetrexed Combined with Conventional Chemotherapy in Patients with Stage Ⅲ-Ⅳ Non-small Cell Lung Cancer

目的探讨培美曲塞联合常规化疗在Ⅲ~Ⅳ期非小细胞肺癌患者中的应用价值。方法在该医院2015年1月—2018年12月期间诊治的Ⅲ~Ⅳ期非小细胞肺癌患者中方便选取40例予以化学治疗:将接受常规化疗(多西他赛联合顺铂)者设为对照组(n=20),而接受培美曲塞联合常规化疗(培美曲塞联合顺铂)者设为研究组(n=20),比较两组患者化疗效果、血清肿瘤标志物差异。结果①研究组患者近期肿瘤控制率45.00%高于对照组的10.00%(χ^2=5.177,P=0.023);②治疗后,研究组CEA、CYFRA21-1水平均低于对照组(t=6.791、11.210,P=0.000)。结论培美曲塞联合常规化疗在Ⅲ~Ⅳ期非小细胞肺癌患者中的应用价值显著,可优化近期化疗效果,并改善其肿瘤血清标志物指标,值得借鉴。

Objective To investigate the value of pemetrexed combined with conventional chemotherapy in patients with stage Ⅲ~Ⅳ non-small cell lung cancer. Methods Conveniently selected 40 patients with stage Ⅲ~Ⅳ non-small cell lung cancer who were treated in the hospital from January 2015 to December 2018 were treated with chemotherapy. Patients who received conventional chemotherapy(docetaxel plus cisplatin) were selected as the control group(n=20), and those who received pemetrexed combined with conventional chemotherapy(pemetrexed plus cisplatin) were enrolled in the study group(n =20). The chemotherapy effect and serum tumor markers were compared between the two groups. Results 1.The tumor control rate of the study group was 45.00% higher than that of the control group 10.00%(χ^2=5.177, P=0.023). 2.After treatment, the CEA and CYFRA21-1 levels in the study group were lower than the control group(t=6.791,11.210, P =0.000).Conclusion The combination of pemetrexed and conventional chemotherapy in patients with stage Ⅲ~Ⅳ non-small cell lung cancer is significant. It can optimize the effect of recent chemotherapy and improve the serum markers of tumors. It is worth learning.